DVA

$149.31-0.45 (-0.30%)

Market ClosedAs of Mar 20, 8:00 PM UTC

DaVita Inc.

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$149.31
Potential Downside
149%
Whystock Fair Value$-73.12
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Care Facilities

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpa...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$9.98B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
15.70
Beta
Defensive asset. Lower volatility than the S&P 500.
0.93
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-128.44%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.24

Recent News

Barchart
Mar 20, 2026

DaVita Stock: Is DVA Outperforming the Health Care Sector?

DaVita has outperformed the Health Care sector recently, but analysts are cautious about the stock’s prospects.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 19, 2026

DaVita’s Strong Operations Confront Debt Warning And Insider Selling Signals

DaVita (NYSE:DVA) reports strong operational performance with solid revenue growth and expanding margins. The company now faces early warning signals, including a distress-level Altman Z-Score that flags potential financial risk. Recent insider selling activity at DaVita adds another layer of concern for investors tracking internal confidence. DaVita, a major provider of kidney care services, sits at the intersection of aging demographics, chronic disease trends and ongoing pressure on...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 18, 2026

Zacks Industry Outlook Highlights Quest Diagnostics, DaVita, Option Care Health and Addus HomeCare

DGX, DVA, OPCH and ADUS gain attention as telehealth, AI adoption and aging population drive growth in home healthcare services.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 17, 2026

DaVita HealthCare (DVA) Beats Stock Market Upswing: What Investors Need to Know

In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $149.98, denoting a +1.19% move from the preceding trading day.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Zacks
Mar 17, 2026

4 Outpatient Home Health Stocks Gaining Attention Amid Market Shifts

An aging population and rising AI adoption boost demand in the Zacks Medical - Outpatient and Home Healthcare industry. DGX, DVA, OPCH and ADUS stand to benefit.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.